Scholar Rock

Biologics

SRK-181 Clin1 immuno-oncology; 2 undisclosed programs RD/Clin0 anemia, fibrosis

Scholar Rock is discovering new medicines that target inactive forms of growth factors to treat disease. Growth factors in their active form are common therapeutic targets, since they are extracellular and drivers of disease. However, many mature, active forms of different growth factors are structurally similar, limiting drug specificity. Scholar Rock is targeting the inactive precursor, or latent, forms of growth factors to regulate their activity in the tissue microenvironment. To identify therapeutics, Scholar Rock is using their proprietary platform to develop antibody drugs that recognise the prodomain of precursor growth factors. Scholar Rock’s lead candidate, Apitegromab, is in Phase 3 clinical trials for patients with Spinal Muscular Atrophy.